The treatment of dyslipidemia is dominated by statins, used as monotherapy or in combination with ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and fibrates, which have been demonstrated to be effective in lipid-lowering and cardiovascular risk reduction. Here, PCSK9 is linked to metabolic syndrome.